Jeremy Chadwick Sells 24,727 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 24,727 shares of the firm’s stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $80.26, for a total transaction of $1,984,589.02. Following the transaction, the chief operating officer directly owned 61,202 shares in the company, valued at $4,912,072.52. This trade represents a 28.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Kymera Therapeutics Trading Up 6.1%

Shares of KYMR traded up $4.51 during mid-day trading on Wednesday, hitting $78.93. The company’s stock had a trading volume of 934,950 shares, compared to its average volume of 769,289. The company’s 50-day moving average is $79.80 and its 200-day moving average is $70.30. Kymera Therapeutics, Inc. has a 52-week low of $19.44 and a 52-week high of $103.00. The firm has a market capitalization of $6.44 billion, a price-to-earnings ratio of -21.45 and a beta of 2.20.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The business had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The business’s quarterly revenue was down 60.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.88) earnings per share. As a group, sell-side analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Baker BROS. Advisors LP lifted its holdings in shares of Kymera Therapeutics by 30.2% during the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after purchasing an additional 2,005,813 shares during the period. Avoro Capital Advisors LLC boosted its position in Kymera Therapeutics by 17.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after buying an additional 1,124,747 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Kymera Therapeutics by 20.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after buying an additional 1,061,957 shares during the period. Vanguard Group Inc. increased its holdings in Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after buying an additional 845,922 shares during the period. Finally, Holocene Advisors LP purchased a new position in Kymera Therapeutics during the 3rd quarter worth approximately $47,563,000.

Analyst Ratings Changes

A number of brokerages have recently issued reports on KYMR. Mizuho lifted their price target on Kymera Therapeutics from $81.00 to $120.00 and gave the company an “outperform” rating in a report on Thursday, December 11th. Jefferies Financial Group started coverage on Kymera Therapeutics in a research note on Monday, March 16th. They set a “buy” rating and a $110.00 price objective for the company. Leerink Partners raised their price objective on Kymera Therapeutics from $70.00 to $118.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Thursday, January 22nd. Finally, Barclays boosted their target price on shares of Kymera Therapeutics to $133.00 and gave the stock an “overweight” rating in a report on Tuesday, January 27th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $118.90.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.